Prinaberel

Prinaberel (also known as ERB-041) is a synthetic, orally active and selective estrogen receptor beta (ERβ) agonist which was under development by Wyeth but was ultimately discontinued. It was being investigated for the treatment of rheumatoid arthritis and inflammatory bowel disease and had completed Phase II clinical trials for these indications.

Pharmacology

Prinaberel selectively binds to and activates ERβ, one of two main types of estrogen receptor. The activation of ERβ has anti-inflammatory effects and can be beneficial in the treatment of conditions like rheumatoid arthritis and inflammatory bowel disease.

Clinical trials

Prinaberel has completed Phase II clinical trials for the treatment of rheumatoid arthritis and inflammatory bowel disease. However, the development of the drug was discontinued by Wyeth.

See also

• Estrogen receptor beta
• Wyeth
• Rheumatoid arthritis
• Inflammatory bowel disease
• Phase II clinical trials

References

Prinaberel Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski